ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update
August 09, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data
June 17, 2019 17:00 ET
|
ContraFect Corporation
YONKERS, N.Y., June 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
June 06, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
June 03, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
May 31, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
May 10, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., May 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,...
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease
May 08, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 04, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, New York, April 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect to Present at the Bacteriophage Therapy Summit
March 21, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 14, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., March 14, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...